Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer

HYPOTHESIS: The majority of non-small cell lung cancer (NSCLC) patients treated with anti-PD-1/PD-L1 therapy develop either innate or acquired resistance. Across tumor types, the “T cell-inflamed” tumor microenvironment correlates with clinical response to immunotherapy. We hypothesize that clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Shalin, Wood, Kevin, Labadie, Brian, Won, Brian, Brisson, Ryan, Karrison, Theodore, Hensing, Thomas, Kozloff, Mark, Bao, Riyue, Patel, Jyoti D., Luke, Jason J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796980/
https://www.ncbi.nlm.nih.gov/pubmed/29435109
http://dx.doi.org/10.18632/oncotarget.23315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796980/
https://www.ncbi.nlm.nih.gov/pubmed/29435109
http://dx.doi.org/10.18632/oncotarget.23315

Ejemplares similares